About BeiGene

Website
Website
Employees
Employees
1,001-5,000 employees View all
Industry
Industry
biotechnology
Location
Location
55 Cambridge Parkway,Cambridge,MA,US
Description
Information
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.See our community guidelines: bit.ly/39o3O6j

BeiGene Alternatives

Industry
biotechnology
Industry
Biotechnology
Industry
Biotechnology
Industry
Biotechnology
Industry
Biotechnology
Industry
Biotechnology

Frequently Asked Questions about BeiGene

What is BeiGene email format?

The widely used BeiGene email format is {first}.{last} (e.g. [email protected]) with 87.5% adoption across the company.


What is BeiGene customer service number?

To contact BeiGene customer service number in your country click here to find.


Who is the CEO of BeiGene?

John Oyler is the CEO of BeiGene. To contact John Oyler email at [email protected], [email protected] or [email protected].


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more